Spago Nanomedical AB (SPAGO) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.201x

Based on the latest financial reports, Spago Nanomedical AB (SPAGO) has a cash flow conversion efficiency ratio of -0.201x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.19 Million ≈ $-665.71K USD) by net assets (Skr30.75 Million ≈ $3.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SPAGO cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Spago Nanomedical AB - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Spago Nanomedical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Spago Nanomedical AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Spago Nanomedical AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Genuit Group plc LSE:GEN	0.035x
LCC Infotech Limited NSE:LCCINFOTEC	0.267x
Phoenix New Media Limited NYSE:FENG	-0.002x
ENENSYS Technologies SA PA:ALNN6	-0.839x
Jungo Connectivity Ltd TA:JNGO	N/A
Manhattan Corporation Ltd AU:MHC	-0.037x
Nyrstar NV BR:NYR	0.000x
Metal Bank Ltd AU:MBK	-0.024x

Annual Cash Flow Conversion Efficiency for Spago Nanomedical AB (2011–2025)

The table below shows the annual cash flow conversion efficiency of Spago Nanomedical AB from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see SPAGO company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr30.75 Million ≈ $3.31 Million	Skr-28.30 Million ≈ $-3.05 Million	-0.920x	+11.77%
2024-12-31	Skr33.23 Million ≈ $3.58 Million	Skr-34.67 Million ≈ $-3.73 Million	-1.043x	+4.03%
2023-12-31	Skr41.32 Million ≈ $4.45 Million	Skr-44.91 Million ≈ $-4.83 Million	-1.087x	-461.18%
2022-12-31	Skr197.16 Million ≈ $21.22 Million	Skr-38.19 Million ≈ $-4.11 Million	-0.194x	-0.64%
2021-12-31	Skr184.81 Million ≈ $19.89 Million	Skr-35.57 Million ≈ $-3.83 Million	-0.192x	-63.76%
2020-12-31	Skr159.67 Million ≈ $17.18 Million	Skr-18.77 Million ≈ $-2.02 Million	-0.118x	+24.02%
2019-12-31	Skr137.63 Million ≈ $14.81 Million	Skr-21.29 Million ≈ $-2.29 Million	-0.155x	-79.87%
2018-12-31	Skr122.22 Million ≈ $13.15 Million	Skr-10.51 Million ≈ $-1.13 Million	-0.086x	-19.90%
2017-12-31	Skr107.78 Million ≈ $11.60 Million	Skr-7.73 Million ≈ $-831.87K	-0.072x	+34.47%
2016-12-31	Skr71.84 Million ≈ $7.73 Million	Skr-7.86 Million ≈ $-846.18K	-0.109x	-33.92%
2015-12-31	Skr65.41 Million ≈ $7.04 Million	Skr-5.34 Million ≈ $-575.21K	-0.082x	+23.04%
2014-12-31	Skr56.05 Million ≈ $6.03 Million	Skr-5.95 Million ≈ $-640.53K	-0.106x	+47.60%
2013-12-31	Skr38.18 Million ≈ $4.11 Million	Skr-7.74 Million ≈ $-832.62K	-0.203x	-1324.77%
2012-12-31	Skr42.25 Million ≈ $4.55 Million	Skr-601.00K ≈ $-64.68K	-0.014x	+33.80%
2011-12-31	Skr12.84 Million ≈ $1.38 Million	Skr-276.00K ≈ $-29.70K	-0.021x	--

About Spago Nanomedical AB

ST:SPAGO Sweden Biotechnology

Market Cap

$8.37 Million

Skr77.73 Million SEK

Market Cap Rank

#27481 Global

#606 in Sweden

Share Price

Skr0.12

Change (1 day)

+4.91%

52-Week Range

Skr0.09 - Skr0.40

All Time High

Skr19.04